Article

New Antiproliferative Compounds against Glioma Cells from the Marine-Sourced Fungus *Penicillium* sp. ZZ1750

Kuo Yong †, **Sidra Kaleem** †, **Bin Wu** * and **Zhizhen Zhang** *

Ocean College, Zhejiang University, Zhoushan Campus, Zhoushan 316021, China; yongkuo@zju.edu.cn (K.Y.); kaleemsidra85@yahoo.com (S.K.)
* Correspondence: wubin@zju.edu.cn (B.W.); zzhang88@zju.edu.cn (Z.Z.); Tel.: +86-136-7585-9706 (Z.Z.)
† Both the authors contribute equally to this paper.

Abstract: Seven novel compounds, namely peniresorcinosides A–E (**1**–**5**), penidifarnesylin A (**6**), and penipyridinone A (**7**), together with the 11 known ones **8**–**17**, were isolated from a culture of the marine-associated fungus *Penicillium* sp. ZZ1750 in rice medium. The structures of the new compounds were established based on their high-resolution electrospray ionization mass spectroscopy (HRESIMS) data, extensive nuclear magnetic resonance (NMR) spectroscopic analyses, chemical degradation, Mosher's method, ^{13}C-NMR calculations, electronic circular dichroism (ECD) calculations, and single crystal X-ray diffraction. Peniresorcinosides A (**1**) and B (**2**) are rare glycosylated alkylresorcinols and exhibited potent antiglioma activity, with IC$_{50}$ values of 4.0 and 5.6 μM for U87MG cells and 14.1 and 9.8 μM for U251 cells, respectively.

Keywords: marine fungus; *Penicillium* sp. ZZ1750; peniresorcinosides A–E; penidifarnesylin A; penipyridinone A; structure elucidation; antiglioma activity

1. Introduction

Gliomas are one of the most common types of primary brain tumors and despite advances in cancer therapy, have remained particularly challenging to treat [1]. Gliomas usually locate at many important brain function areas, which makes surgical resection very difficult, therefore, chemotherapy has played a more important role in the treatment and prevention of glioma. However, most of the current anti-glioma drugs, such as temozolomide (the first line chemotherapeutic agent for glioma), carmustine, lomustine, and procarbazine, are DNA cytotoxic alkylating agents with drug resistance, serious toxicity, and other side-effects [2,3]. Although antibodies (such as bevacizumab) and molecularly targeted anticancer drugs are constantly being evaluated for the treatment of glioma, their overall curative effect is poor [4]. Therefore, the discovery and development of new anti-glioma drugs with unique mechanisms of action is an urgent need.

Marine fungi are important resources for the discovery of novel bioactive natural products and drug lead compounds [5–11]. Among them, *Penicillium* species fungi have been proved to be one of the most novel bioactive compound producers [9–11]. For example, 390 new compounds with different structural types were identified from the marine-derived *Penicillium* fungi during 1991–2014, of which 58% showed some form of antitumor, antiviral, antibacterial, and anti-inflammatory activity [9]. It was also reported that 188 secondary metabolites with diverse bioactivities were isolated from marine *Penicillium* fungi from 2015 to 2020 [11].

In recent years, we have carried out research on the discovery of natural products from marine microorganisms with antiproliferative activity against human glioma cells. These studies have resulted in the isolation and identification of a number of novel compounds with potent antiglioma activity, including the polycyclic anthraquinones *N*-acetyl-*N*-demethylmayamycin and streptoanthraquinone A from *Streptomyces* sp. 182SMLY [12], the cyclodepsipeptide streptodepsipeptides P11A and P11B from *Streptomyces* sp. P11-23B [13],

bagremycin C from *Streptomyces* sp. Q22 [14], pyrrospirone G and penicipyrroether A from *Penicillium* sp. ZZ380 [15,16], 1-hydroxymethyl-8-hydroxyanthraquinone-3-carboxylic acid from *Streptomyces* sp. ZZ406 [17], streptoglutarimide H from *Streptomyces* sp. ZZ741 [18], and the compounds marinacarbolines G and M and caerulomycin N from *Actinoalloteichus* sp. ZZ1866 [19]. The antiglioma activity of some compounds were related to the downregulation of several important glioma glycolytic enzymes [13,17].

As a part of our ongoing research program to discover novel natural antiglioma products from marine microorganisms, a *Penicillium* sp. ZZ1750 fungus was isolated from a marine mud sample collected from the Arabian Sea, close to Karachi, Pakistan. An ethyl acetate (EtOAc) extract prepared from a scale-up culture of the strain ZZ1750 in rice medium showed antiproliferative activity against human glioma U87MG and U251 cells with inhibition rates of 79.68% and 78.27%, respectively. Chemical investigation of this active extract resulted in the isolation of 17 secondary metabolites, including seven new compounds (Figure 1), namely the peniresorcinosides A–E (compounds **1–5**), penidifarnesylin A (**6**), and penipyridinone A (**7**). Herein, we report the details of the isolation, structure elucidation and antiglioma activity evaluation of all isolated compounds.


Figure 1. Structures of compounds **1–7** isolated from the marine fungus *Penicillium* sp. ZZ1750.

2. Results and Discussion

The marine-sourced strain ZZ1750 (Figure S1, Supplementary Materials) was identified as *Penicillium* sp. ZZ1750 based on its internal transcribed spacer (ITS) rDNA sequence (563 bp, Figure S2), which was a 100% match to those of six other *Penicillium* strains (Table S1). An EtOAc extract prepared from a large-scale culture of the strain ZZ1750 in rich medium was separated by column chromatography, followed by high performance liquid chromatography (HPLC) purification, to afford compounds **1–17**.

Compound **1** was obtained as a yellowish oil with an optical rotation value of + 76 and a UV absorption at 232 nm. Its molecular formula $C_{30}H_{48}O_8$ was deduced from the HRESIMS (high resolution electrospray ionization mass spectroscopy) ion peak at m/z 559.3248 [M + Na]$^+$ (calcd. for $C_{30}H_{48}NaO_8{}^+$, 559.3247) as well as its ^{13}C-NMR data. Analyses of its ^{1}H, ^{13}C, distortionless enhancement by polarization transfer (DEPT), and heteronuclear multiple quantum correlation (HMQC) spectra showed the presence of ten olefinic carbons, six oxymethines, one oxymethylene, one methine, ten methylenes, and two methyls (Table 1). A double peak signal at δ_H 6.02 (2H, d, J = 2.0 Hz, H-2 and H-6) showed HMQC correlation with a carbon signal at δ_C 106.3 (C-2 and C-6) and also showed HMBC (heteronuclear multiple bond correlation) correlation (Figure 2) with the same carbon signal (δ_C 106.3), indicating the presence of a symmetrical structure unit in **1**.

Table 1. ^{13}C-NMR (150 MHz) and ^{1}H-NMR (600 MHz) data of compounds **1**, **1a**, and **2**.

No.	**1** [a]		**1a** [b]		**2** [a]	
	δ_C, Type	δ_H, *J* in Hz	δ_C, Type	δ_H, *J* in Hz	δ_C, Type	δ_H, *J* in Hz
1	143.4, C	–	145.5, C	–	143.4, C	–
2	106.3, CH	6.02, d (2.0)	107.9, CH	6.13, d (2.0)	106.3, CH	6.02, d (2.3)
3	158.2, C	–	159.4, C	–	158.2, C	–
4	100.1, CH	6.00, t (2.0)	101.1, CH	6.08, t (2.0)	100.1, CH	6.01, t (2.3)
5	158.2, C	–	159.4, C	–	158.2, C	–
6	106.3, CH	6.02, d (2.0)	107.9, CH	6.13, d (2.0)	106.3, CH	6.02, d (2.3)
7	35.3, CH$_2$	2.42, t (7.5)	37.1, CH$_2$	2.50, t (7.5)	35.3, CH$_2$	2.42, t (7.6)
8	33.6, CH$_2$	2.23, q (7.5)	35.5 [c], CH$_2$	2.28, q (7.5)	33.6, CH$_2$	2.23, q (7.6)
9	131.3, CH	5.55, m	132.2, CH	5.56, m	131.3, CH	5.55, m
10	130.5, CH	5.96, dd (15.3, 10.7)	131.8, CH	5.99, dd (14.8, 10.5)	130.6, CH	5.96, dd (14.8, 10.3)
11	130.3, CH	5.93, dd (14.8, 10.7)	132.2, CH	5.96, dd (14.8, 10.5)	130.3, CH	5.93, dd (14.8, 10.3)
12	132.3, CH	5.53, m	133.4, CH	5.52, m	132.3, CH	5.53, m
13	31.9, CH$_2$	1.99, q (7.3)	30.8 [e], CH$_2$	2.03, q (7.1)	31.9, CH$_2$	1.99, q (7.3)
14	28.9, CH$_2$	1.32, m	30.6 [d], CH$_2$	1.37, m	28.9, CH$_2$	1.32, m
15	28.6 [c], CH$_2$	1.24 [e], m	30.3 [d], CH$_2$	1.29 [e], m	28.6 [c], CH$_2$	1.24 [e], m
16	28.9 [c], CH$_2$	1.24 [e], m	30.5 [d], CH$_2$	1.29 [e], m	28.9 [c], CH$_2$	1.24 [e], m
17	29.3 [c], CH$_2$	1.24 [e], m	30.8 [e], CH$_2$	1.29 [e], m	29.5 [c], CH$_2$	1.24 [e], m
18	29.2 [c], CH$_2$	1.24 [e], m	27.4, CH$_2$	1.29 [e], m	29.2 [c], CH$_2$	1.24 [e], m
19	24.9 [d], CH$_2$	1.41, m; 1.37, m	35.4 [c], CH$_2$	1.41, m	24.9 [d], CH$_2$	1.42, m; 1.38, m
20	81.0, CH	3.35, m	75.4, CH	3.42, m	81.7, CH	3.35, m
21	37.5, CH	1.58, m	41.5, CH	1.35, m	37.5, CH	1.57, m
22	24.8 [d], CH$_2$	1.48, m; 1.08, m	27.1, CH$_2$	1.49, m; 1.15, m	24.7 [d], CH$_2$	1.48, m; 1.08, m
23	12.0, CH$_3$	0.84, t (7.3)	12.2, CH$_3$	0.90, t (7.3)	11.9, CH$_3$	0.85, t (7.5)
24	14.5, CH$_3$	0.81, d (6.9)	13.9, CH$_3$	0.86, d (6.7)	14.4, CH$_3$	0.82, d (6.8)
25	98.2, CH	4.70, d (3.7)			98.5, CH	4.70, d (3.7)
26	72.1, CH	3.15, dd (9.5, 3.7)			71.9, CH	3.17, m
27	73.0, CH	3.37, t (9.5)			72.9, CH	3.37, t (9.3)
28	70.1, CH	3.07, t (9.5)			70.5, CH	3.00, t (9.3)
29	73.0, CH	3.43, m			70.2, CH	3.66, m
30	60.8, CH$_2$	3.53, dd (11.5, 2.0); 3.46, dd (11.5, 4.7)			64.0, CH$_2$	4.25, dd (11.7, 1.9); 3.95, dd (11.7, 7.3)
1′					170.2, C	–
2′					20.6, CH$_3$	1.98, s
OH-3					–	9.06, br s
OH-26					–	4.59, d (4.9)
OH-27					–	4.89, br s
OH-28					–	5.17, br s

[a,b] The data were recorded in DMSO-d_6 and MeOH-d_4, respectively; [c,d] the data with the same label in each column may be interchanged; [e] The data with the same label in each column were overlapped.

Figure 2. COSY and key HMBC correlations of peniresorcinosides A (**1**) and B (**2**).

Further analysis of HMBC correlations of H-2/6 (δ_H 6.02) with C-3/5 (δ_C 158.2), C-4 (δ_C 100.1), C-6/2 (δ_C 106.3), and C-7 (δ_C 35.3) as well as H-4 (δ_H 6.00, t, 2.0 Hz) with C-2, C-3, C-5, and C-6 demonstrated that the symmetrical structure unit was a resorcinol derivative with a substituent at the C-1 position. This substituent was made up of two hydroxyalkene and hexose moieties. The hydroxyalkene moiety at C-1 was identified as a octadecene with two pairs of double bonds at C$_{9-10}$ and C$_{11-12}$, an oxymethine at C-20, and a methyl at C-21 based on the two COSY (correlation spectroscopy) spin systems of H$_2$-7/H$_2$-8/H-9/H-10/H-11/H-12/H$_2$-13/H$_2$-14/H$_2$-15 and H$_2$-18/H$_2$-19/H-20/H-21(H$_3$-24)/H$_2$-22/H$_3$-23 as well as the key HMBC correlations (Figure 2) of H-2/6 with C-7, H$_2$-7 with C-2, C-6, and C-9, H$_2$-8 with C-1 and C-9, H-10 with C-8 and C-12, H-11 with C-9, H-12 with C-14, H$_2$-13 with C-11 and C-12, H$_2$-14 with C-13 and C-16, H$_2$-15 with C-13 and C-17, H$_2$-16 with C-18, H$_2$-18 with C-20, H$_2$-19 with C-17 and C-20, H$_2$-22 with C-20, H$_3$-23 with C-21 and C-22, H$_3$-24 with C-20, C-21, and C-22.

The large coupling constants of $^3J_{\text{H9-H10}}$ (15.3 Hz) and $^3J_{\text{H11-H12}}$ (14.8 Hz) (Table 1) indicated 9*E* and 11*E* geometries. The hexose moiety resonated at δ_H 4.70 (1H, d, 3.7 Hz, H-25), 3.15 (1H, dd, 9.5, 3.7, H-26), 3.37 (1H, t, 9.5 Hz, H-27), 3.07 (1H, t, 9.5 Hz, H-28), 3.43 (1H, m, H-29), 3.53 (1H, dd, 11.5, 2.0 Hz, H-30a), 3.46 (1H, dd, 11.5, 4.7 Hz, H-30b), and δ_C 98.2 (CH, C-25), 72.1 (CH, C-26), 73.0 (CH, C-27), 70.1 (CH, C-28), 73.0 (CH, C-29), and 60.8 (CH$_2$, C-30), which were assigned by HMQC, COSY and HMBC correlations. Enzymatic hydrolysis of **1** by α-glucosidase produced D-glucose and **1a**, a new compound. The aldonitrile acetate of the hydrolytic D-glucose was identified by gas chromatography (GC) analysis [20] (Figure S3) using the authentic aldonitrile acetates of different sugars (D-glucose, L-glucose, D-galactose, L-galactose) as references. A small coupling constant (3.5 Hz, $^3J_{\text{H25-H26}}$) and a upfield ^{13}C chemical shift (δ_C 98.3, C-25, when compared to δ_C 103.2 for the anomeric carbon of β-D-glucosyl moiety) [21] indicated an α anomeric configuration for the glucose, which was further supported by the fact that only α-glucosidase hydrolyzed this compound. Therefore, the hexose was proved to be an α-D-glucopyranosyl moiety, which was linked to C-20 as established by the HMBC correlations of H-20 (δ_H 3.35) with C-25 and H-25 with C-20 (δ_C 81.0). The planar structure of the aglycone **1a** was established based on its HRESIMS data as well as ^{13}C, ^{1}H, COSY, and HMQC spectroscopic analyses. The configuration at C-20 of **1a** was assigned by the Mosher ester NMR method. Treatment of **1a** with (*R*)-α-methoxy-α-(trifluoromethyl) phenylacetyl chloride (*R*-MTPA-Cl) or *S*-MTPA-Cl gave *S*-MTPA ester (**1as**) or *R*-MTPA ester (**1ar**). The ^{1}H-NMR chemical shift differences ($\Delta\delta_{S-R}$, Figure 3 and Table S2) between **1as** and **1ar** in negative values for H-18 and H-19 and positive values for H-21, H-22, H-23, and H-24 were observed, indicating a 20*S*-configuration for **1a**.

Figure 3. $\Delta\delta_{S\text{-}R}$ values for the MTPA esters **1as** and **1ar** of compound **1a**.

In order to assign the configuration at C-21 and further support the 20*S*-configuration, four possible diastereomers of 20*R*,21*S*-**1a**, 20*S*,21*S*-**1a**, 20*R*,21*R*-**1a**, and 20*S*,21*R*-**1a** were subjected to ^{13}C and ^{1}H-NMR calculations [22,23]. The results (Tables S3–S5) showed that NMR data of **1a** was very close to those of the model molecule 20*S*,21*S*-**1a** with DP4^{+} probability scores of 99.90% for ^{13}C-NMR data, 68.95% for ^{1}H-NMR data, and 99.98% for all NMR data, determining a 20*S*,21*S*-configuration for **1a**. Based on the combined foregoing evidence, the structure of **1** was elucidated as a new glycosylated alkylresorcinol analogue, which was named peniresorcinoside A. The full assignment of its ^{13}C- and ^{1}H-NMR data (Table 1) was made by HMQC, COSY, and HMBC correlations (Figure 2).

Compound **2** was also obtained as a yellowish oil with a similar optical rotation value and UV absorption to those of **1**. The molecular formula $C_{32}H_{50}O_9$ of **2** was deduced from its HRESIMS ion peak at *m/z* 601.3346 [M + Na]$^{+}$, 42 mass units higher than that of **1**, corresponding to a -C_2H_2O group. The IR spectrum of **2** showed an absorption at 1724 cm^{-1}, indicating the presence of a carbonyl group. Detailed comparison of the ^{13}C- and ^{1}H-NMR spectra of **2** and **1** indicated that their chemical shifts bore a very close resemblance, except for two additional ^{13}C-NMR signals (δ_C 170.2 and 20.6) and one extra ^{1}H-NMR signal (δ_H 1.98, 3H, s) for an acetyl observed in the NMR spectra of **2**. The HMBC correlations of H$_2$-30 (δ_H 4.25, dd, *J* = 11.7, 1.9 Hz; 3.95, dd, *J* = 11.7, 7.3) with C-1′ (δ_C 170.2) and H$_3$-2′ (δ_H 1.98) with C-1′ demonstrated the acetyl was at the C-30 position. The difference between the ^{13}C-NMR chemical shifts for C-30 (Δ +3.2 ppm) between **2** and **1** also supported the location of this acetyl group. Compound **2** was thus elucidated as a new glycosylated alkylresorcinol analogue, named peniresorcinoside B. The ^{13}C- and ^{1}H-NMR data (Table 1) were fully assigned based on the HMQC, COSY, and HMBC correlations (Figure 2).

Compound **3** was obtained as a yellowish oil. Its HRESIMS spectrum showed ion peaks at *m/z* 775.5719 [M + H]$^{+}$ and 797.5543 [M + Na]$^{+}$, corresponding to a molecular formula $C_{46}H_{78}O_9$, which was 16 carbons, 30 protons, and one oxygen more than that of **1**. Careful analyses of the ^{13}C- and ^{1}H-NMR spectra of **3** and **1** demonstrated that **3** and **1** shared the same glycosylated alkylresorcinol structural backbone. Compared to the NMR signals of **1**, compound **3** showed additional NMR signals for a carbonyl (δ_C 172.7), a methyl (δ_C 13.9; δ_H 0.84, 3H, t, *J* = 7.0 Hz), and some methylenes, whose NMR signals were high overlapped. Based on these characteristic NMR signals, in consideration of the presence of additional 16 carbons and one oxygen in **3**, it was deduced that compound **3** had a structural unit of sixteen-carbon saturated acid (palmitic acid). The HMBC correlations of H$_2$-30 (δ_H 4.26, 1H, d, *J* = 10.8; 3.95, 1H, dd, *J* = 10.8, 7.3 Hz) with C-1′ (δ_C 172.7) established the linkage of this sixteen-carbon unit. Therefore, compound **3** was elucidated as a new glycosylated alkylresorcinol analogue, and named peniresorcinoside C. Its ^{13}C- and ^{1}H- NMR data (Table 2) were assigned based on the HMQC, COSY, and HMBC correlations (Figure S4).

Table 2. ^{13}C-NMR (150 MHz) and ^{1}H-NMR (600 MHz) data (in DMSO-d_6) of compounds **3–5**.

No.	3		4		5	
	δ_C, Type	δ_H, *J* in Hz	δ_C, Type	δ_H, *J* in Hz	δ_C, Type	δ_H, *J* in Hz
1	143.4, C	–	143.4, C	–	143.4, C	–
2	106.3, CH	6.02, d (1.9)	106.3, CH	6.02, d (1.9)	106.3, CH	6.02, d (1.8)
3	158.2, C	–	158.2, C	–	158.2, C	–
4	100.1, CH	6.01, t (1.9)	100.1, CH	6.01, t (1.9)	100.1, CH	6.01, t (1.8)
5	158.2, C	–	158.2, C	–	158.2, C	–
6	106.3, CH	6.02, d (1.9)	106.3, CH	6.02, d (1.9)	106.3, CH	6.02, d (1.8)
7	35.3, CH$_2$	2.42, t (7.3)	35.3, CH$_2$	2.42, t (7.4)	35.3, CH$_2$	2.42, t (7.3)
8	33.6 [a], CH$_2$	2.22, q (7.5)	33.7 [a], CH$_2$	2.23 [e], q (7.4)	33.6 [a], CH$_2$	2.22, q (7.3)
9	131.3, CH	5.55, m	131.3, CH	5.55, m	131.3, CH	5.54, m
10	130.5, CH	5.95, dd (15.0, 10.5)	130.5, CH	5.95, dd (15.1, 10.7)	130.5, CH	5.95, dd (15.6, 10.6)
11	130.2, CH	5.93, dd (15.0, 10.5)	130.2, CH	5.93, dd (15.1, 10.7)	130.3, CH	5.93, dd (15.6, 10.6)
12	132.3, CH	5.52, m	132.3, CH	5.52, m	132.3, CH	5.52, m
13	31.9, CH$_2$	1.99, q (7.5)	32.0, CH$_2$	2.00 [f], q (7.3)	32.0, CH$_2$	1.98, q (7.4)
14	28.9 [b], CH$_2$	1.32, m	28.9 [b], CH$_2$	1.32, m	28.9 [b], CH$_2$	1.32, m
15	28.6 [b], CH$_2$	1.23 [e], m	28.6 [b], CH$_2$	1.24 [g], m	28.6 [b], CH$_2$	1.23 [e], m
16	28.9 [b], CH$_2$	1.23 [e], m	28.9 [b], CH$_2$	1.24 [g], m	28.9 [b], CH$_2$	1.23 [e], m
17	29.3 [b], CH$_2$	1.23 [e], m	29.3 [b], CH$_2$	1.24 [g], m	29.3 [b], CH$_2$	1.23 [e], m
18	29.2 [b], CH$_2$	1.23 [e], m	29.2 [b], CH$_2$	1.24 [g], m	29.2 [b], CH$_2$	1.23 [e], m
19	24.9 [e], CH$_2$	1.41, m; 1.37, m	24.9 [e], CH$_2$	1.40, m; 1.36, m	24.9 [e], CH$_2$	1.41, m; 1.36, m
20	81.0, CH	3.35, m	81.1, CH	3.35, m	81.1, CH	3.35, m
21	37.5, CH	1.57, m	37.5, CH	1.56, m	37.5, CH	1.57, m
22	24.9 [e], CH$_2$	1.49, m; 1.12, m	24.9 [e], CH$_2$	1.49, m; 1.11, m	24.9 [e], CH$_2$	1.49, m; 1.11, m
23	12.0, CH$_3$	0.85, t (7.3)	12.0, CH$_3$	0.85, t (7.4)	12.0, CH$_3$	0.85, t (7.3)
24	14.3, CH$_3$	0.82, d (6.7)	14.4, CH$_3$	0.82, d (6.9)	14.3, CH$_3$	0.82, d (6.8)
25	98.0, CH	4.70, d (3.8)	98.1, CH	4.70, d (3.9)	98.0, CH	4.70, d (3.7)
26	71.8, CH	3.16, m	71.9, CH	3.18, m	71.9, CH	3.17, m
27	72.7, CH	3.39, m	72.8, CH	3.39, m	72.8, CH	3.39, m
28	70.6, CH	2.98, m	70.6, CH	2.98, m	70.6, CH	2.98, m
29	70.2, CH	3.66, t (8.6)	70.2, CH	3.66, t (8.5)	70.2, CH	3.66, t (8.8)
30	64.3, CH$_2$	4.26, d (10.8); 3.95, dd (10.8, 7.3)	64.1, CH$_2$	4.27, d (11.2); 3.95, dd (11.2, 7.5)	64.1, CH$_2$	4.27, d (11.2); 3.95, dd (11.2, 7.5)
1′	172.7, C	–	172.7, C	–	172.7, C	–
2′	33.5 [a], CH$_2$	2.25, t (7.2)	33.6 [a], CH$_2$	2.23 [e], t (7.4)	33.6 [a], CH$_2$	2.23, t (7.3)
3′	24.4, CH$_2$	1.50, m	24.4, CH$_2$	1.50, m	24.4, CH$_2$	1.50, m
4′	29.0 [b], CH$_2$	1.23 [e], m	28.7 [b], CH$_2$	1.24 [g], m	28.7 [b], CH$_2$	1.23 [e], m
5′	29.0 [b], CH$_2$	1.23 [e], m	28.5 [b], CH$_2$	1.24 [g], m	28.5 [b], CH$_2$	1.23 [e], m
6′	29.0 [b], CH$_2$	1.23 [e], m	28.5 [b], CH$_2$	1.24 [g], m	28.5 [b], CH$_2$	1.23 [e], m
7′	29.0 [b], CH$_2$	1.23 [e], m	28.4 [b], CH$_2$	1.24 [g], m	28.4 [b], CH$_2$	1.23 [e], m
8′	28.9 [b], CH$_2$	1.23 [e], m	26.6 [f], CH$_2$	2.00 [f], q (7.3)	26.5 [f], CH$_2$	1.95 [f], q (7.0)
9′	28.8 [b], CH$_2$	1.23 [e], m	129.7 [c], CH	5.28 [h], m	129.7 [c], CH	5.29 [g], m
10′	28.8 [b], CH$_2$	1.23 [e], m	127.8 [d], CH	5.31 [i], m	129.6 [c], CH	5.29 [g], m

Table 2. *Cont.*

No.	3		4		5	
	δ_C, Type	δ_H, *J* in Hz			δ_C, Type	δ_H, *J* in Hz
11′	28.8 [b], CH_2	1.23 [e], m	25.2, CH_2	2.72, t (6.6)	26.5 [f], CH_2	1.95 [f], q (7.0)
12′	28.7 [b], CH_2	1.23 [e], m	127.7 [d], CH	5.28 [h], m	29.0 [b], CH_2	1.23 [e], m
13′	28.4 [b], CH_2	1.23 [e], m	129.6 [c], CH	5.31 [i], m	28.8 [b], CH_2	1.23 [e], m
14′	31.3, CH_2	1.23 [e], m	26.6 [f], CH_2	2.00 [f], q (7.3)	28.6 [b], CH_2	1.23 [e], m
15′	22.1, CH_2	1.23 [e], m	29.0 [b], CH_2	1.24 [g], m	29.0 [b], CH_2	1.23 [e], m
16′	13.9, CH_3	0.84, t (7.0)	30.9, CH_2	1.24 [g], m	31.3, CH_2	1.23 [e], m
17′	–	–	22.0, CH_2	1.24 [g], m	22.1, CH_2	1.23 [e], m
18′	–	–	13.9, CH_3	0.84, t (7.3)	13.9, CH_3	0.83, t (7.0)
OH-3/5	–	9.04, s	–	9.05, s	–	9.06, s
OH-26	–	4.57, d (6.1)	–	4.57, d (6.1)	–	4.59, d (6.0)
OH-27	–	4.85, d (4.2)	–	4.85, br s	–	4.88, br s
OH-28	–	5.15, d (5.6)	–	5.15, d (5.5)	–	5.17, d (5.3)

[a−d] The data with the same label in each column may be interchanged; [e−i] The data with the same label in each column were overlapped.

The HRESIMS spectrum of **4** gave ion peaks at *m/z* 799.5716 [M + H]⁺ and 821.5536 [M + Na]⁺, matching a molecular formula of $C_{48}H_{78}O_9$, 18 carbons, 30 protons, and one oxygen more than that of **1**. Analyses of the ^{13}C- and ^{1}H-NMR spectra of **4** and **1** led to the conclusion that **4** also had the same glycosylated alkylresorcinol structural unit of **1**. Compared to the NMR signals of **1**, compound **4** exhibited additional NMR signals for a carbonyl (δ_C 172.7), two pairs of double bonds (δ_C 129.7, 129.6, 127.8, 127.7; δ_H 5.28, 2H, m, 5.31, 2H, m), a methyl (δ_C 13.9; δ_H 0.84, 3H, t, *J* = 7.3 Hz), and some signal-overlapped methylenes. These characteristic NMR signals, together with the fact of additional 18 carbons and one oxygen in **4** mentioned above, suggested that compound **4** had an eighteen-carbon unsaturated fatty acid structural unit. Alkaline hydrolysis of **4** gave peniresorcinoside A (**1**) as determined by co-HPLC analysis (Figure S5) with the authentic sample and 9(Z),12(Z)-octadecadienoic acid (linoleic acid, **4a**) based on its NMR data (Table S9) and the comparison with the reference data [24,25] as well as co-HPLC analysis (Figure S6) with standard linoleic acid. The HMBC correlations of H₂-30 (δ_H 4.27, 1H, d, *J* = 11.2; 3.95, 1H, dd, *J* = 11.2, 7.5 Hz) with C-1′ (δ_C 172.7) demonstrated this linoleic acid unit at C-30 position. The structure of **4** was thus identified as a new glycosylated alkylresorcinol analogue, named peniresorcinoside D. Its ^{13}C- and ^{1}H-NMR data (Table 2) were assigned based on the HMQC, COSY, and HMBC correlations (Figure S4).

The molecular formula $C_{48}H_{80}O_9$ of **5** was determined based on its HRESIMS ions at *m/z* 823.5694 [M + Na]⁺, two mass units higher than that of **4**. Detailed analyses of the ^{13}C- and ^{1}H-NMR spectra of **5** and **4** indicated that the structures of both compounds had the same glycosylated alkylresorcinol backbone with a difference in the number of double bonds of the eighteen-carbon unsaturated fatty acid unit. The ^{13}C- and ^{1}H-NMR spectra of **5** only exhibited a pair of double bonds (δ_C 129.7, 129.6; δ_H 5.29, 2H, m), instead of the two pairs of double bonds in **4**.

Alkaline hydrolysis of **5** also gave peniresorcinoside A (**1**) as confirmed by co-HPLC analysis (Figure S5) and octadecenoic acid (oleic acid, **5a**), as determined by analyzing its ^{13}C- and ^{1}H-NMR data (Table S9), comparing with the reference data [26], and co-HPLC analysis (Figure S7) with an oleic acid standard. This oleic acid unit connected to C-30 was established through the HMBC correlations of H₂-30 (δ_H 4.27, 1H, d, *J* = 11.2; 3.95, 1H, dd, *J* = 11.2, 7.5 Hz) with C-1′ (δ_C 172.7). The structure of **5** was elucidated as a new glycosylated alkylresorcinol analogue, named peniresorcinoside E. The ^{13}C-

and ^{1}H-NMR data (Table 2) of **5** were assigned based on its HMQC, COSY, and HMBC correlations (Figure S4).

Compound **6** was obtained as orthorhombic crystals from a mixture solvent of EtOAc and CHCl$_3$ (1:1) and its HRESIMS ion peak at *m/z* 497.3604 [M + Na]$^+$, corresponding to a molecular formula C$_{30}$H$_{50}$O$_4$. However, only 15 carbon signals were observed in the ^{13}C NMR spectrum, suggesting its symmetrical structure. The 15 carbon signals were assigned for six olefin carbons, two oxymethine carbons, three methylene carbons, and four methyl carbons (Table 3) based on its HMQC spectrum. The half planar structure (C$_1$-C$_{15}$) of **6** was established as a farnesyl derivative by further analyses of its COSY and HMBC correlations (Figure 4). A HMBC correlation of H$_2$-12 (δ_H 1.92, 2H, m) with C-12′ (δ_C 27.9, CH$_2$), in consideration of its molecular formula, suggested the whole planer structure of **6**, which was further confirmed by its crystal structure (Figure 5) obtained from X-ray diffraction analysis. However, the data from the X-ray diffraction was not good enough for the assignment of the absolute configuration of **6** because of a poor Flack parameter of 0.3 (3). Therefore, a computational method was applied to assign the absolute configuration of **6** by comparing its experimental electronic circular dichroism (ECD) spectrum with the calculated ECD spectra. The X-ray CIF profile of **6** (5*R*,8*R*,5′*R*,8′*R*-**6**) and its enantiomer (5*S*,8*S*,5′*S*,8′*S*-**6**) were initially optimized at B3LYP/6-31g (d, p) level in MeOH. The theoretical calculations of ECD were conducted in MeOH using Time-dependent Density functional theory (TD-DFT) at the B3LYP/6-311+g (d, p) level. The results (Figure 6) showed that the experimental ECD spectrum of **6** was agreement with the calculated ECD curve of the model molecule 5*R*,8*R*,5′*R*,8′*R*-**6**, indicating a 5*R*,8*R*,5′*R*,8′*R*-configuration for **6**. Based on the foregoing evidence, the structure of **6** was determined to correspond to a new dimeric farnesene derivative, named penidifarnesylin A. Its ^{13}C and ^{1}H NMR data (Table 3) were assigned according to the HMQC, COSY, and HMBC correlations (Figure 4).

**Table 3.** ^{13}C NMR (150 MHz) and ^{1}H NMR (600 MHz) data of penidifarnesylin A (**6**) (in DMSO-d_6).

No.	[13]C, Type	[1]H (*J* in Hz)	No.	[13]C, Type	[1]H (*J* in Hz)
1/1′	25.6, CH$_3$	1.63, s	10/10′	131.9, C	–
2/2′	131.2, C	–	11/11′	126.1, CH	5.08, t (6.3)
3/3′	121.6, CH	5.02, t (7.6)	12/12′	27.9, CH$_2$	1.92 ^{a}, m
4/4′	34.2, CH$_2$	2.06, m; 1.99, m	13/13′	17.7, CH$_3$	1.54, s
5/5′	76.1, CH	3.73, m	14/14′	11.2, CH$_3$	1.50, s
6/6′	137.2, C	–	15/15′	16.5, CH$_3$	1.56, s
7/7′	129.5, CH	5.16, d (8.2)	OH-5/5′	–	4.64, d (3.6)
8/8′	65.7, CH	4.25, m	OH-8/8′	–	4.41, d (4.6)
9/9′	48.1, CH$_2$	2.10, m; 1.92 ^{a}, m			

^{a} Data with the same label in each column were overlapped.

Figure 4. COSY and key HMBC correlations of penidifarnesylin A (**6**).

Figure 5. Crystal structure of penidifarnesylin A (**6**) (Cu Kα radiation, displacement ellipsoids are drawn at the 30% probability level).

Figure 6. Experimental ECD spectrum of penidifarnesylin A (**6**, 190–450 nm) and calculated ECD spectrum of 5*R*,8*R*,5′*R*,8′*R*-**6** and 5*S*,8*S*,5′*S*,8′*S*-**6** at the b3lyp/6-311+g (d, p) level in MeOH.

Table 4. ^{13}C-NMR (150 MHz) and ^{1}H-NMR (600 MHz) data of penipyridinone A (**7**, in DMSO-d_6).

No	^{13}C, Type	^{1}H (*J* in Hz)	No	^{13}C, Type	^{1}H (*J* in Hz)
1	69.7, CH$_2$	3.69, dd (11.5, 1.7); 3.56, dd (11.5, 2.3)	14	13.6, CH$_3$	0.87, t (7.4)
2	31.5, CH	2.27, m	15	10.5, CH$_3$	0.94, d (7.0)
3	80.3, CH	3.42, dd (9.5, 5.5)	16	11.5, CH$_3$	1.66, s
4	70.0, CH	4.84, t (9.5)	17	55.7, CH$_3$	3.25, s
5	83.7, CH	3.58, d (9.5)	18	167.5, C	–
6	132.8, C	–	19	52.7, CH$_2$	4.85, d (18.2); 4.75, d (18.2)
7	129.3, CH	5.97, d (10.1)	20	148.7, C	–
8	125.9, CH	6.29, dd (15.0, 10.1)	21	117.7, CH	5.98, d (2.8)
9	134.2, CH	6.24, dd (15.0, 10.1)	22	177.8, C	–
10	130.7, CH	6.13, dd (15.6, 10.1)	23	116.0, CH	5.93, dd (8.0, 2.8)
11	135.3, CH	5.74, m	24	142.7, CH	7.41, d (8.0)
12	34.3, CH$_2$	2.05, m	25	18.4, CH$_3$	2.01, s
13	21.9, CH$_2$	1.36, m			

The molecular formula of **7** was defined as $C_{25}H_{35}NO_5$ based on its HRESIMS ion peaks at *m/z* 430.2587 [M + H]$^+$ and 452.2406 [M + Na]. Analyses of its ^{1}H-, ^{13}C- and HMQC NMR spectra demonstrated the presence of two carbonyls, ten olefin carbons, eight olefin protons, three oxymethines, one oxymethylene, one methoxy, one methine, three methylenes, and four methyls (Table 4). The two carbonyls and ten olefin carbons (five pairs of double bonds) accounted for seven out of the nine degrees of unsaturation required by the molecular formula, suggesting that **7** had a structure with two rings. Two COSY spin systems of H$_2$-1/H-2(H$_3$-15)/H-3/H-4/H-5 and H-7/H-8/H-9/H-10/H-

11/H$_2$-12/H$_2$-13/H$_3$-14 and the HMBC correlations as described in Figure 7 determined that the first cycle-related partial structure (**7a**, Figure 7) was a tetrahydropyran derivative. Similarly, the second cycle-related partial structure (**7b**) was established as a pyridinone derivative by the COSY correlation of H-23 (δ_H 5.93, dd, 8.0, 2.8 Hz) with H-24 (δ_H 7.41, d, 8.0 Hz) and the HMBC correlations (Figure 7). A HMBC correlation of H-4 (δ_H 4.84, t, 9.5 Hz) with C-18 (δ_C 167.5) demonstrated the connection of the two partial structures of **7a** and **7b**.


Figure 7. COSY, key HMBC, and NOE correlations of penipyridinone A (**7**).

The relative configurations of **7** were assigned based on the coupling constants and nuclear Overhauser effect (NOE) information. A small coupling constant of 5.5 Hz ($^3J_{H2-H3}$) and the large coupling constants of 9.5 Hz ($^3J_{H3-H4}$ and $^3J_{H4-H5}$) (Table 4) suggested a β-orientation for H-4 and an α-orientation for H-2, H-3, and H-5 [27]. The 6*E* geometry was assigned by the NOE correlations of H-7 (δ_H 5.97, d, 10.1 Hz) with H-9 (δ_H 6.24, dd, 15.0, 10.1 Hz) as well as H-8 (δ_H 6.29, dd, 15.0, 10.1 Hz) with H-10 (δ_H 6.13, dd, 15.6, 10.1 Hz) and H$_3$-16 (δ_H 1.66, s), whereas the 8*E* and 10*E* geometries were determined based on their *trans*-coupling constants of 15.0 Hz for $^3J_{H8-H9}$ and 15.6 Hz for $^3J_{H10-H11}$. These assigned configurations for **7** were the same as those of restrictinol (**7c**) [28,29]. Based on the forgoing evidences, the structure of **7** was elucidated as a new restrictinol analogue with a unique pyridinone functionality, named penipyridinone A. Its ^{13}C- and ^{1}H-NMR data (Table 4) were assigned based on the HMQC, COSY, HMBC, and NOESY correlations (Figure 7).

Based on the NMR data and optical rotation values as well as the comparison with the reported data, compounds **8**–**17** were identified as known compounds methyl linoleate (**8**) [30], 12β-hydroxyverruculogen TR-2 (**9**) [31,32], 12β-hydroxy-13α-methoxyverruculogen TR-2 (**10**) [31,33], cyclotryprostatin B (**11**) [34], verruculogen (**12**) [34], fumiquinazoline C (**13**) [35], fumiquinazoline J (**14**) [35,36], brevianamide F (**15**) [37,38], 2-[(2*R*-hydroxypropanoyl)amino] benzamide (**16**) [39], and trypacidin (**17**) [40,41]. The ^{13}C and ^{1}H NMR data of compounds **8**–**17** are reported in Tables S9–S13.

All isolated compounds **1**–**17** were tested for their antiproliferative activity against human glioma U87MG and U251 cells by using the Sulforhodamine B (SRB) assay [42]. Doxorubicin (DOX, an anticancer drug) was used as a positive control. The results (Table 5) showed that peniresorcinosides A (**1**) and B (**2**) had potent antiglioma activity with IC$_{50}$ values of 4.0 and 5.6 µM for U87MG cells and 14.1 and 9.8 µM for U251 cells, respectively. Penidifarnesylin A (**6**) also showed antiproliferative activity with IC$_{50}$ values of 5.9 µM against U87MG cells and 27.6 µM against U251 cells. However, peniresorcinosides C–E (**3**–**5**) with a long-chain fatty acid unit only showed antiproliferative activity against U87MG cells with IC$_{50}$ values of 53.0, 19.4, and 22.1 µM, respectively. Other tested compounds were inactive at a concentration of 50 µM.

Marine-derived *Penicillium* fungi are still important sources for the discovery of novel bioactive natural products. The current study described the isolation and structural elucidation of 17 metabolites, including new glycosylated alkylresorcinols of peniresorcinosides A–E (**1**–**5**), penidifarnesylin A (**6**), and penipyridinone A (**7**) as well as some known indole

alkaloids with complicated structures, from the marine fungus *Penicillium* sp. ZZ1750 cultured in rice medium.

Alkylresorcinols are resorcinol units alkylated with a long odd-numbered carbon chain and had high levels (over 500 μg/g) in wheat, rye, and triticale [43]. It has been reported that some of alkylresorcinols exhibited antimicrobial, antiparasitic, and cytotoxic activities [44]. Resorcinosides A and B [45], recently isolated from the marine fungus *Penicillium janthinellum*, are the first reported alkylresorcinol derivatives containing a glucose moiety linked to a hydroxy group of the alkyl side chain. Peniresorcinosides A–E (**1–5**) are second example of this type of rare glycosylated alkylresorcinols. Peniresorcinosides C–E (**3–5**) have more complicated structures, with a long-chain fatty acid moiety attached to the C-6 position of the glucosyl unit. Evaluation of the antiglioma activity showed that peniresorcinosides A (**1**) and B (**2**) had potent antiproliferative activity against both glioma U87MG and U251 cells, while peniresorcinosides C–E (**3–5**) only exhibited moderate antiglioma activity against U87MG cells.

Table 5. Antiproliferative activity of compounds against human glioma cells (IC$_{50}$: μM).

Compound	U87MG	U251	Compound	U87MG	U251
1	4.0 ± 0.2	14.1 ± 0.4	**5**	22.1 ± 0.3	NA
2	5.6 ± 0.5	9.8 ± 0.9	**6**	5.9 ± 0.3	27.6 ± 1.8
3	53.0 ± 1.0	NA	Doxorubicin	0.5 ± 0.0	3.5 ± 0.4
4	19.4 ± 1.6	NA			

NA: No activity at a concentration of 50 μM.

The cyclotryprostatin [34,46], fumiquinazoline [35,46–48], and verruculogen [31,34] indole alkaloids were most frequently isolated from *Aspergillus* and *Penicillium* fungi. Some of them have reported antibacterial, antifungal, cytotoxic, and antidiabetic activities [48,49]. In this study, seven such known indole alkaloids (compounds **9–15**) were obtained from the metabolites produced by the marine-sourced *Penicillium* fungus ZZ1750. Fumiquinazoline C (**13**) was previously reported to have moderate cytotoxicity against murine lymphocytic leukemia P388 cells [47]. However, none of these isolated indole alkaloids **9–15** were active against human glioma U87MG and U251 cells at a concentration of 50 μM.

3. Materials and Methods

3.1. General Experimental Procedures

Melting points (m.p.) were measured with a WRX-4 microscope apparatus (Shanghai Yice Apparatus & Equipment Co. Ltd., Shanghai, China) and was uncorrected. Ultraviolet (UV), optical rotation (OR), electronic circular dichroism (ECD), and infrared radiation (IR) spectra were measured on a METASH UV-8000 (Shanghai METASH Instruments Co. Ltd., Shanghai, China), an Autopol I Automatic polarimeter (Rudolph Research Analytical, Hackettstown, NJ, USA), a J-815 spectropolarimeter (JASCO Co. Tokyo, Japan), and a Nicolet^{TM} IS^{TM} 10 FT-IR spectrometer (Thermo Fisher Scientific, Waltham, MA, USA), respectively. NMR data were acquired on a JEOL 600 spectrometer (JEOL, Tokyo, Japan) using a standard JEOL pulse sequences for 1D and 2D (HMQC, COSY, HMBC, and NOESY) NMR experiments and chemical shifts were expressed in δ (ppm) relative to DMSO-d_6 (δ_C 39.5, δ_H 2.50) or MeOH-d_4 (δ_C 49.0, δ_H 3.31). HRESIMS data were obtained on a 6230 Time of Flight Liquid Chromatography/Mass Spectrometry (TOF LC/MS) spectrometer (Agilent Technologies, Palo Alto, CA, USA). X-ray diffraction analysis was carried out on an Xcalibur Atlas Gemini Ultra diffractometer (Agilent Technologies) with Cu Kα radiation (λ = 1.54184 Å) at 100 K. Silica gel (200–300 mesh, Qingdao Ocean Chemical Plant, Qingdao, China) and octadecyl-functionalized silica gel (ODS, Cosmosil 75C$_{18}$-Prep, Nacalai Tesque Inc., Kyoto, Japan) were used for column chromatography. HPLC separation was performed on an Agilent 1260 HPLC system using Agilent Zorbax SB-C$_{18}$ column (250 × 9.2 mm, 5 μm) or a CXTH LC-3000 preparative HPLC system

(Beijing Chuangxin Tongheng Science & Technology Co. Ltd., Beijing, China) using a CT-30 column (Fuji-C_{18}, 280 × 30 mm, 10 μm). GC analysis was conducted on a GC-2010 system (Shimadzu, Kyoto, Japan) equipped with an SH-Rtx-5 capillary column (30 m × 0.32 mm, 0.25 μm). Nitrogen gas was used as the carrier gas and flame ionization detection (FID) was used as detector. Both injection port and detector temperatures were fixed at 280 °C. The column temperature was set at 180 to 280 °C in 10 min with an increase of 10 °C/min. Solvents used for this study were purchased from the Sinopharm Chemical Reagent Co. Ltd. (Shanghai, China). Mosher's reagents (*R*)-(–)-α-methoxy-α-(trifluoromethyl) phenylacetyl chloride (*R*-MTPA-Cl) and *S*-MTPA-Cl were ordered from Aladdin Industrial Corporation (Shanghai, China). Human glioma U87MG (JDS-2568) and U251 (XB-0439) cells were ordered from the Cell Bank of the Chinese Academy of Sciences, Shanghai, China. Linoleic acid (>95.0%) and oleic acid (>99.0%) were purchased from Shanghai Aladdin Biochemical Technology Co., Ltd, and doxorubicin (DOX, >98.0%) from Sigma-Aldrich (St. Louis, MO, USA). Different culture media were made in the laboratory, including Gauze's synthetic medium (B, soluble starch 20 g, KNO_3 1 g, $MgSO_4 \cdot 7H_2O$ 0.5 g, NaCl 0.5 g, K_2HPO_4 0.5 g, $FeSO_4$ 0.01 g, agar 20 g, water 1 L), Gauze's synthetic medium with sea salt (BS, soluble starch 20 g, KNO_3 1 g, $MgSO_4 \cdot 7H_2O$ 0.5 g, NaCl 0.5 g, K_2HPO_4 0.5 g, $FeSO_4$ 0.01 g, agar 20 g, sea salt 35 g, water 1 L), potato dextrose agar medium (PDA, potatoes 200 g, glucose 20 g, agar 20 g, boiled into 1 L of water for 15 min), potato dextrose agar medium with sea salt (PDAS, potatoes 200 g, glucose 20 g, agar 20 g, sea salt 35 g, boiled into 1 L of water for 15 min), William's E medium (E, yeast 1.0 g, tryptone 5.0 g, $FeCl_3 \cdot 6H_2O$ 0.17 g, KH_2PO_4 0.12 g, agar 30 g, water 1 L), William's E medium with sea salt (ES, yeast 1.0 g, tryptone 5.0 g, $FeCl_3 \cdot 6H_2O$ 0.17 g, KH_2PO_4 0.12 g, agar 30 g, sea salt 35 g, water 1 L), international *Streptomyces* project medium-2 (ISP-2, yeast extract 4 g, malt extract 10 g, dextrose 4.0 g, peptone 5 g, agar 20 g, water 1 L), international *Streptomyces* project medium-2 with sea salt (ISP-2S, yeast extract 4 g, malt extract 10 g, dextrose 4.0 g, peptone 5 g, agar 20 g, sea salt, 35 g, water 1 L), international *Streptomyces* project medium-4 (ISP-4, soluble starch 10 g, K_2HPO_4 1 g, $MgSO_4 \cdot 7H_2O$ 1 g, NaCl 1 g, $(NH_4)_2SO_4$ 2 g, $CaCO_3$ 2 g, $FeSO_4$ 1 mg, $MnCl_2$ 1 mg, $ZnSO_4$ 1 mg, agar 20 g, water 1 L), international *Streptomyces* project medium-4 with sea salt (ISP-4S, soluble starch 10 g, K_2HPO_4 1 g, $MgSO_4 \cdot 7H_2O$ 1 g, NaCl 1 g, $(NH_4)_2SO_4$ 2 g, $CaCO_3$ 2 g, $FeSO_4$ 1 mg, $MnCl_2$ 1 mg, $ZnSO_4$ 1 mg, agar 20 g, sea salt, 35 g, water 1 L).

3.2. Isolation and Taxonomic Identification of Strain ZZ1750

The strain ZZ1750 was isolated from a sample of marine mud, which was collected from the Arabian Sea near Karachi, Sindh, Pakistan in January 2019. Briefly, the mud sample was air dried at 28 °C for 7 days and the dried sample (1.0 g) was diluted with sterile water to make up the dilutions of 10^{-2}, 10^{-3}, and 10^{-4} g/mL. Each dilution (200 μL) was transferred on the surface of ten different solid media of B, BS, PDA, PDAS, E, ES, ISP-2, ISP-2S, ISP-4, and ISP-4S on Petri dishes and then incubated at 28 °C for 14 days. The single colony of ZZ1750 was picked from the 10^{-2} g/mL suspension in PDA medium and then transferred to another PDA medium in dish. After growth for another 7 days at 28 °C, the single pure colony (ZZ1750) that grew well was transferred onto PDA slant medium and stored at 4 °C for further study.

The ITS rDNA sequence analysis of strain ZZ1750 was conducted by Legenomics (Hangzhou Lizhen Biotechnology Co., Ltd., Hangzhou, China). The ITS rDNA sequence was compared to those in the GenBank database using the nucleotide Basic Local Alignment Search Tool (BLAST). The ITS rDNA sequence of strain ZZ1750 has been deposited in GenBank (accession number: MT159428). The strain *Penicillium* sp. ZZ1750 was preserved at the Laboratory of Institute of Marine Biology and Pharmacology, Ocean College, Zhoushan campus, Zhejiang University, Zhoushan, China.

3.3. Mass Culture of Strain ZZ1750

The colony of strain ZZ1750 from the PDA slant medium was inoculated into a 500 mL Erlenmeyer flask, which contained 250 mL potato dextrose broth (PDB) medium and then incubated for 3 days in a shaker (180 rpm, 28 °C) to produce the seed broth (Figure S1). The seed broth (5 mL) was transferred into rice medium (40 g rice, 60 mL 3.5% sea salt solution) in 500 mL Erlenmeyer flask and then all these flasks were incubated at 28 °C for 30 days in a static state. For this study, a total of 210 cultured flasks were prepared.

3.4. Extraction and Isolation of Compounds 1–17

The culture of strain ZZ1750 in rice medium in each flask was extracted with EtOAc (250 mL) three times. The combined EtOAc extract was dried in vacuo to give an extract (100 g). This extract was fractionated on a column (160 × 10 cm) of silica gel (1600 g) eluting with a mixture of cyclohexane and EtOAc in different ratios (10:1, 5:1, 2:1, 1:1, 1:2, each 1000 mL) to give four fractions of Frs. A–D based on the results of TLC analyses.

Fr. A was separated by using an Agilent 1260 HPLC system equipped with an Agilent Zorbax SB-C_{18} column (250 × 9.4 mm, 5 μm; mobile phase: ACN/H_2O, 62/38; flow rate: 1.0 mL/min; UV detection: 232 nm) to give **6** (15.0 mg, t_R 29.6 min) and **1** (15.2 mg, t_R 34.5 min).

Fr. B was first separated on an ODS (200 g) column (530 × 35 mm) eluting with 60%, 70%, 80%, and 90% MeOH (each 1000 mL) to yield four subfractions (SFrs. B_1–B_4) according to the TLC analytic results. SFr. B_1 was further separated on a Fuji-C_{18} CT-30 column (280 × 30 mm, 10 μm; mobile phase: $MeOH/H_2O$, 75/25; flow rate: 10 mL/min; UV detection: 210 nm) to give **2** (4.0 mg, t_R 34.5 min). SFr.B_2 was also separated on the same CT-30 column using the same flow rate and same UV detection, but a different mobile phase of $MeOH/H_2O$ (70/30), to give **10** (2.5 mg; t_R 24.0 min) and **12** (12.2. mg; t_R 37.5 min). SFr.B_4 was separated on the Zorbax SB-C_{18} column (mobile phase: $MeOH/H_2O$, 95/5; flow rate: 1.0 mL/min, UV detection: 232 nm) to furnish **4** (2.8 mg, t_R 58.8 min), **3** (2.6 mg, t_R 72.0 min), and **5** (3.3 mg, t_R 76.8 min). Compound **8** (3.2 mg, t_R 31.1 min) was obtained from SFr.B_5 through purification on the Zorbax SB-C_{18} column (mobile phase: $MeOH/H_2O$, 98/2; flow rate: 1.0 mL/min, UV detection: 210 nm).

In the same way, SFr. B_3 was further separated on the CT-30 column (mobile phase: $MeOH/H_2O$, 67/33; flow rate: 10 mL/min; UV detection: 210 nm) to give parts B_{3a}–B_{3c}. By using the Zorbax SB-C_{18} column (flow rate: 1.0 mL/min), compounds **9** (20 mg, t_R 36.4 min, ACN/H_2O, 55/45), **11** (1.5 mg; t_R 40.4 min, ACN/H_2O, 50/50; UV detection: 210 nm), and **7** (3.8 mg, t_R 41 min, $MeOH/H_2O$, 87/13; UV detection of 275 nm) were purified from B_{3a}, B_{3b}, and B_{3c}, respectively.

Similarly, Fr. C was fractionated on the CT-30 column (mobile phase: $MeOH/H_2O$, 60/40; flow rate: 10 mL/min; UV detection: 210 nm) to afford parts C_1 and C_2. Then, by using the Zorbax SB-C_{18} column (flow rate: 1.0 mL/min; UV detection: 210 nm), compound **17** (8.0 mg, t_R 25.0 min, mobile phase: $MeOH/H_2O$, 65/35) was purified from part C_1, **13** (21.0 mg, t_R 30.0 min) and **14** (4.7 mg, t_R 28.0 min, mobile phase: $MeOH/H_2O$, 63/35) were obtained from part C_2.

Finally, Fr. D was separated by using the Zorbax SB-C_{18} column (mobile phase: ACN/H_2O, 40/60; flow rate: 1.0 mL/min; UV detection: 232 nm) to give **15** (2.8 mg, t_R 26.6 min) and **16** (2.1 mg, t_R 36 min).

Peniresorcinoside A (**1**): Yellowish oil; molecular formula $C_{30}H_{48}O_8$; $[\alpha]^{20}_D$ +76° (*c* 0.10, MeOH); UV (MeOH) λ_{max} (log ε) 232 (3.45) nm; IR (ATR) ν_{max} 3354, 2912, 2843, 1593, 1452, 1155, 1020, 982, 835 cm^{-1}; ^{13}C-NMR (150 MHz) and ^1H-NMR (600 MHz) data (in DMSO-d_6), see Table 1; HRESIMS *m/z* 559.3248 $[M + Na]^+$ (calcd for $C_{30}H_{48}NaO_8^+$, 559.3247).

Peniresorcinoside B (**2**): Yellowish oil; molecular formula $C_{32}H_{50}O_9$; $[\alpha]^{20}_D$ +80° (*c* 0.10, MeOH); UV (MeOH) λ_{max} (log ε) 232 (3.46) nm; IR (ATR) ν_{max} 3398, 2912, 1724, 1606, 1450, 1146, 1034, 609 cm^{-1}; ^{13}C-NMR (150 MHz) and ^1H-NMR (600 MHz) data (in DMSO-d_6), see Table 1; HRESIMS *m/z* 601.3346 $[M + Na]^+$ (calcd for $C_{32}H_{50}NaO_9^+$, 601.3353).

Peniresorcinoside C (**3**): White amorphous powder; molecular formula $C_{46}H_{78}O_9$; $[\alpha]^{20}_D$ +28° (c 0.1, CH_3OH); UV (MeOH) λ_{max} (log ε) 233 (3.99); IR (ATR) ν_{max} 3333, 2922,

2855, 1714, 1600, 1510, 1455, 1076, 1018, 841 cm^{-1}; ^{13}C-NMR (150 MHz) and ^{1}H-NMR (600 MHz) data (in DMSO-d_6), see Table 2; HRESIMS m/z 775.5719 [M + H]$^+$ (calcd for C$_{46}$H$_{79}$O$_9^+$, 775.5724) and 797.5543 [M + Na]$^+$ (calcd for C$_{46}$H$_{78}$NaO$_9^+$, 797.5544).

Peniresorcinoside D (**4**): White amorphous powder; molecular formula C$_{48}$H$_{78}$O$_9$; [α]$^{20}_D$ +42° (c 0.1, CH$_3$OH); UV (MeOH) λ_{max} (log ε) 233 (4.34); IR (ATR) ν_{max} 3355, 2924, 2857, 1722, 1592, 1457, 1145, 1104, 1016, 986, 840 cm^{-1}; ^{13}C-NMR (150 MHz) and ^{1}H-NMR (600 MHz) data (in DMSO-d_6), see Table 2; HRESIMS m/z 799.5716 [M + H]$^+$ (calcd for C$_{48}$H$_{79}$O$_9^+$, 799.5724) and 821.5536 [M + Na]$^+$ (calcd for C$_{48}$H$_{78}$NaO$_9^+$, 821.5544).

Peniresorcinoside E (**5**): White amorphous powder; molecular formula C$_{48}$H$_{80}$O$_9$; [α]$^{20}_D$ +40° (c 0.1, CH$_3$OH); UV (MeOH) λ_{max} (log ε) 233 (4.22); IR (ATR) ν_{max} 3343, 2922, 2855, 1716, 1598, 1459, 1149, 1059, 984, 841 cm^{-1}; ^{13}C-NMR (150 MHz) and ^{1}H-NMR (600 MHz) data (in DMSO-d_6), see Table 2; HRESIMS m/z 823.5694 [M + Na]$^+$ (calcd for C$_{48}$H$_{80}$NaO$_9^+$, 823.5700).

Penidifarnesylin A (**6**): Orthorhombic crystals (EtOAc:CHCl$_3$, 1: 1); molecular formula C$_{30}$H$_{50}$O$_4$; m.p. 145–148 °C; [α]$^{20}_D$ +40° (c 0.10, MeOH); ECD (200 μg/mL, MeOH) λ_{max} ($\Delta\varepsilon$) 210 (+7.62) nm; UV (MeOH) λ_{max} (log ε) 210 (4.24) nm; IR (ATR) ν_{max} 3347, 2921, 2853, 1440, 1376, 1260, 1020 cm^{-1}; ^{13}C-NMR (150 MHz) and ^{1}H-NMR (600 MHz) data (in DMSO-d_6), see Table 3; HRESIMS m/z 497.3604 [M + Na]$^+$ (calcd for C$_{30}$H$_{50}$NaO$_4^+$, 497.3607). Crystal data of penidifarnesylin A (**6**): C$_{30}$H$_{50}$O$_4$ (M = 474.70 g/mol), orthorhombic, space group P2$_1$2$_1$2 (no. 18), a = 7.4649(8) Å, b = 59.512(10) Å, c = 9.9356(16) Å, V = 4413.9(12) Å^3, Z = 6, T = 100.00(12) K, μ(Cu Kα) = 0.536 mm^{-1}, $Dcalc$ = 1.072 g/cm^3, 29803 reflections measured (5.94° $\leq$ 2Θ $\leq$ 148.752°), 8796 unique (R_{int} = 0.1650, R$_{sigma}$ = 0.1369), which were used in all calculations. The final R_1 was 0.0877 (I > 2σ (I)) and wR_2 was 0.2366 (all data). The crystal data and structure refinement parameters of penidifarnesylin A (**6**) were also reported in Table S6. Crystallographic data of penidifarnesylin A (**6**) has been deposited at the Cambridge Crystallographic Data Centre (CCDC Number: 1976942). Copies of the data can be obtained free of charge from Cambridge Crystallographic Data Centre, 12, Union Road, Cambridge CB2 1EZ, U.K. [fax (+44)1223-336-033; or e-mail: data_request@ccdc.cam.ac.uk].

Penipyridinone A (**7**): Light-yellow powder; molecular formula C$_{25}$H$_{35}$NO$_5$; ^{13}C-NMR (150 MHz) and ^{1}H-NMR (600 MHz) data (in DMSO-d_6), see Table 4; HRESIMS m/z 430.2587 [M + H]$^+$ (calcd for C$_{25}$H$_{36}$NO$_5^+$ 430.2593) and 452.2406 [M + Na]$^+$ (calcd for C$_{25}$H$_{35}$NNaO$_5^+$ 452.2413).

Methyl linoleate (**8**): White amorphous powder; molecular formula C$_{19}$H$_{34}$O$_2$; ^{13}C-NMR (150 MHz) and ^{1}H-NMR (600 MHz) data (in DMSO-d_6), see Table S9; HRESIMS m/z 295.2626 [M + H]$^+$ (calcd for C$_{19}$H$_{35}$O$_2^+$, 295.2637) and 317.2451 [M + Na]$^+$ (calcd for C$_{19}$H$_{34}$NaO$_2^+$, 317.2457).

12β-Hydroxyverruculogen TR-2 (**9**): White amorphous powder; molecular formula C$_{22}$H$_{27}$N$_3$O$_6$; [α]$^{20}_D$ +51° (c 0.10, MeOH); ^{13}C-NMR data (150 MHz, in DMSO-d_6), see Table S10, ^{1}H-NMR data (600 MHz, in DMSO-d_6), see Table S11; HRESIMS m/z 430.1977 [M + H]$^+$ (calcd for C$_{22}$H$_{28}$N$_3$O$_6^+$, 430.1978) and 452.1794 [M + Na]$^+$ (calcd for C$_{22}$H$_{27}$N$_3$NaO$_6^+$, 452.1798).

12β-Hydroxy-13α-methoxyverruculogen TR-2 (**10**): White powder; molecular formula C$_{23}$H$_{29}$N$_3$O$_6$; [α]$^{20}_D$ +45° (c 0.10, MeOH); ^{13}C-NMR data (150 MHz, in DMSO-d_6), see Table S10, ^{1}H-NMR data (600 MHz, in DMSO-d_6), see Table S11; HRESIMS m/z 444.2123 [M + H]$^+$ (calcd for C$_{23}$H$_{30}$N$_3$O$_6^+$, 444.2135) and 466.1946 [M + Na]$^+$ (calcd for C$_{23}$H$_{29}$N$_3$NaO$_6^+$, 466.1954).

Cyclotryprostatin B (**11**): Yellow powder; molecular formula C$_{23}$H$_{27}$N$_3$O$_5$; [α]$^{20}_D$ +59° (c 0.10, MeOH); ^{13}C-NMR data (150 MHz, in CDCl$_3$), see Table S10, ^{1}H-NMR data (600 MHz, in in CDCl$_3$), see Table S11; HRESIMS m/z 426.2029 [M + H]$^+$ (calcd for C$_{23}$H$_{28}$N$_3$O$_5^+$, 426.2029) and 448.1837 [M + Na]$^+$ (calcd for C$_{23}$H$_{27}$N$_3$NaO$_5^+$, 448.1848).

Verruculogen (**12**): White powder; molecular formula C$_{27}$H$_{33}$N$_3$O$_7$; [α]$^{20}_D$ −37.8° (c 0.10, MeOH); ^{13}C-NMR data (150 MHz, in DMSO-d_6), see Table S10, ^{1}H-NMR data

(600 MHz, in DMSO-d_6), see Table S11; HRESIMS *m/z* 512.2410 [M + H]$^+$ (calcd for $C_{27}H_{34}N_3O_7^+$, 512.2397) and 534.2202 [M + Na]$^+$ (calcd for $C_{27}H_{33}N_3NaO_7^+$, 534.2216).

Fumiquinazoline C (**13**): Light-yellow amorphous powder; molecular formula $C_{24}H_{21}N_5O_4$; [α]$^{20}_D$ −60.8° (*c* 0.10, MeOH); ^{13}C-NMR data (150 MHz, in DMSO-d_6), see Table S12, ^{1}H-NMR data (600 MHz, in DMSO-d_6), see Table S13; HRESIMS *m/z* 444.1666 [M + H]$^+$ (calcd for $C_{24}H_{22}N_5O_4^+$, 444.1672) and 466.1486 [M + Na]$^+$ (calcd for $C_{24}H_{21}N_5NaO_4^+$, 466.1491).

Fumiquinazoline J (**14**): White amorphous powder; molecular formula $C_{21}H_{16}N_4O_2$; [α]$^{20}_D$ −68° (*c* 0.10, MeOH); ^{13}C-NMR data (150 MHz, in DMSO-d_6), see Table S12, ^{1}H-NMR data (600 MHz, in DMSO-d_6), see Table S13; HRESIMS *m/z* 357.1343 [M + H]$^+$ (calcd for $C_{21}H_{17}N_4O_2^+$, 357.1352) and 379.1156 [M + Na]$^+$ (calcd for $C_{21}H_{16}N_4NaO_2^+$, 379.1171).

Brevianamide F (**15**): White colorless solid; molecular formula $C_{16}H_{17}N_3O_2$; [α]$^{20}_D$ −53° (*c* 0.10, MeOH); ^{13}C-NMR data (150 MHz, in DMSO-d_6), see Table S12, ^{1}H-NMR data (600 MHz, in DMSO-d_6), see Table S13; HRESIMS *m/z* 284.1396 [M + H]$^+$ (calcd for $C_{16}H_{18}N_3O_2^+$, 284.1399) and 306.1213 [M + Na]$^+$ (calcd for $C_{16}H_{17}N_3NaO_2^+$, 306.1218).

2-[(2*R*-Hydroxypropanoyl) amino] benzamide (**16**): White amorphous powder; molecular formula $C_{10}H_{12}N_2O_3$; [α]$^{20}_D$ +30° (*c* 0.10, MeOH); ^{13}C-NMR data (150 MHz, in DMSO-d_6), see Table S12, ^{1}H-NMR data (600 MHz, in DMSO-d_6), see Table S13; HRESIMS *m/z* 209.0921 [M + H]$^+$ (calcd for $C_{10}H_{13}N_2O_3^+$, 209.0926) and 231.0744 [M + Na]$^+$ (calcd for $C_{10}H_{12}N_2NaO_3^+$, 231.0746).

Trypacidin (**17**): White powder; molecular formula $C_{18}H_{16}O_7$; [α]$^{20}_D$ −50° (*c* 0.10, MeOH); ^{13}C-NMR data (150 MHz, in DMSO-d_6), see Table S12, ^{1}H-NMR data (600 MHz, in DMSO-d_6), see Table S13; HRESIMS *m/z* 345.0969 [M + H]$^+$ (calcd for $C_{18}H_{17}O_7^+$, 345.0974) and 367.0787 [M + Na]$^+$ (calcd for $C_{18}H_{16}NaO_7^+$, 367.0794).

3.5. Enzymatic Hydrolysis of Peniresorcinoside A (*1*)

Peniresorcinoside A (**1**, 3.0 mg) was equilibrated at 37 °C for 5 min in a solution of water (2.0 mL) and 0.1 M phosphate buffer (pH = 7.0, 2.0 mL) and then 0.5 mL of α-glucosidase solution (0.2 M potassium phosphate solution containing 1 mM EDTA and 0.05% Tween-20, pH 7.0) was added. The mixture was incubated at 37 °C for 1 h and then 2.0 mL of 0.2 M Na_2CO_3 solution were added to terminate the enzymatic reaction. The enzymatic product was extracted with EtOAc (each 5 mL) three times to give an EtOAc extract and a water solution. The EtOAc extract was separated on an Agilent Zorbax SB-C18 column (250 × 9.4 mm, 5 μm; mobile phase: MeOH/H_2O, 85/15; flow rate: 1.0 mL/min, UV detection: 210 nm) to furnish **1a** (1.8 mg, t_R 37.4 min). The aqueous solution was dried under reduced pressure to afford a residue which was first treated with 10 mg hydroxylamine hydrochloride in 2 mL pyridine at 90 °C for 30 min in a water bath and then mixed with 2 mL acetic anhydride at 90 °C for 1 h in a water bath. Finally, the reaction products were dried in vacuo and dissolved in 2 mL chloroform for GC analysis. The aldonitrile acetate of sugar in **1** was identified as the aldonitrile acetate of D-glucose (t_R 7.20 min) (Figure S3) by GC analysis with aldonitrile acetates of D-glucose (t_R 7.20 min), L-glucose (t_R 7.28 min), D-galactose (t_R 7.40 min), and L-galactose (t_R 7.45 min) as references.

Compound **1a**: White amorphous powder; molecular formula $C_{24}H_{38}O_3$; ^{13}C-NMR (150 MHz) and ^{1}H-NMR (600 MHz) data (in MeOH-d_4), see Table 1; HRESIMS *m/z*: 375.2893 [M + H]$^+$ (calcd for $C_{24}H_{39}O_3^+$, 375.2899) and 397.2715 [M + Na]$^+$ (calcd for $C_{24}H_{38}NaO_3^+$, 397.2719).

3.6. MTPA Esterification of Compound *1a*

Compound **1a** (0.8 mg) was dissolved in the anhydrous pyridine (0.5 mL) and then either (*R*)-α-methoxy-α-(trifluoromethyl)-phenylacetyl chloride (*R*-MTPA-Cl, 45 μL) or *S*-MTPA-Cl (45 μL) was added. The mixtures were stirred at 45 °C for 48 h until adding 1 mL MeOH to terminate the reaction. The reaction mixtures were dried under reduced pressure to give a residue. (*S*)-MTPA ester **1as** (0.4 mg, t_R 25.1 min, MeOH/H_2O, 100/0)

or (*R*)-MTPA ester **1ar** (0.4 mg, t_R 24.9 min, MeOH/H_2O, 100/0) was obtained from the residue by HPLC purification using an Agilent Zorbax SB-C_{18} column (250 × 9.2 mm, 5 µm) at a flow rate of 1.0 mL/min and UV detection of 210 nm.

Compound **1as**: Molecular formula $C_{54}H_{59}F_9O_9$; ^{1}H-NMR data (600 MHz, in MeOH-d_4), see Table S2; HRESIMS *m/z*: 1045.3910 [M + Na]$^+$ (calcd for $C_{54}H_{59}F_9NaO_9^+$, 1045.3913).

Compound **1ar**: Molecular formula $C_{54}H_{59}F_9O_9$; ^{1}H-NMR data (600 MHz, in MeOH-d_4), see Table S2; HRESIMS *m/z*: 1045.3911 [M + Na]$^+$ (calcd for $C_{54}H_{59}F_9NaO_9^+$, 1045.3913).

3.7. Alkaline Hydrolysis of Peniresorcinosides D (*4*) and E (*5*)

Peniresorcinoside D (**4**, 1.6 mg) was hydrolyzed in 4 mL 3 N NaOH at 40 °C for 2 h in a water bath. The reaction mixture was neutralized with 3 N HCl and then extracted with EtOAc (each 5 mL) three times to give an EtOAc extract. This EtOAc extract was separated on a Zorbax SB-C_{18} column (250 × 9.4 mm, 5 µm; mobile phase: MeOH/0.1%TFA-H_2O, 93/7; flow rate: 1.0 mL/min; UV detection: 210 nm) to give **1** (0.8 mg, t_R 12.8 min) and **4a** (0.5 mg, t_R 35.1 min). In the same way, alkaline hydrolysis of peniresorcinoside E (**5**, 2.1 mg) produced **1** (1.2 mg, t_R 34.5 min) and **5a** (0.7 mg, t_R 45.2 min).

Compound **4a**: Light yellow oil; molecular formula $C_{18}H_{32}O_2$; ^{13}C NMR (150 MHz) and ^{1}H NMR (600 MHz) data (in DMSO-d_6), see Table S9; HRESIMS *m/z* 279.2316 [M − H]$^+$ (calcd for $C_{18}H_{31}O_2^-$, 279.2324).

Compound **5a**: Colorless oil; molecular formula $C_{18}H_{34}O_2$; ^{13}C NMR (150 MHz) and ^{1}H NMR (600 MHz) data (in DMSO-d_6), see Table S9; HRESIMS *m/z* 283.2645 [M + H]$^+$ (calcd for $C_{18}H_{35}O_2^+$, 283.2637) and 305.2445 [M + Na]$^+$ (calcd for $C_{18}H_{34}NaO_2^+$, 305.2457).

3.8. ^{13}C- and ^{1}H-NMR Calculations

Monte Carlo conformational searches were carried out by means of the Spartan's 10 software using Merck Molecular Force Field (MMFF). The conformers with Boltzmann-population of over 5% for NMR calculations were initially optimized at B3LYP/6-31g (d, p) level in MeOH. Gauge-independent atomic orbital (GIAO) calculations of ^{13}C and ^{1}H NMR chemical shifts were accomplished by density functional theory (DFT) at the mPWLPW91-SCRF (DMSO)/6-311+g (d, p) level with the PCM solvent continuum model in Gaussian 09 software. The calculated NMR data of the lowest energy conformers for model molecules 20*R*,21*S*-**1a**, 20*S*,21*S*-**1a**, 20*R*,21*R*-**1a**, and 20*S*,21*R*-**1a** were averaged according to the Boltzmann distribution theory and their relative Gibbs free energy. The ^{13}C-NMR and ^{1}H-NMR chemical shifts for TMS were calculated by the same protocol as reported in the reference [23] and the experimental and calculated data of the isomeric compounds were analyzed by the improved probability DP4$^+$ method [23]. A significant higher DP4$^+$ probability score of the model molecules suggested the correctness of its configuration.

3.9. ECD Calculations

The X-ray CIF profile of 5*S*,8*S*,5′*S*,8′*S*-**6** was initially optimized at B3LYP/6-31g (d, p) level in MeOH. The theoretical calculation of ECD was conducted in MeOH using Time-dependent Density functional theory (TD-DFT) at the B3LYP/6-311+g (d, p) level. Under the same conditions, the enantiomer 5*R*,8*R*,5′*R*,8′*R*-**6** was also calculated. Rotatory strengths for a total of 30 excited states were calculated. ECD spectra were generated using the program SpecDis 1.6 (University of Würzburg, Würzburg, Germany) and GraphPad Prism 5 (University of California San Diego, San Diego, CA, USA) from dipole-length rotational strengths by applying Gaussian band shapes with sigma = 0.2 eV.

3.10. Sulforhodamine B (SRB) Assay

Human glioma U87MG and U251 cells were cultured in Minimum Essential Medium (MEM, Gibco, Thermo Fisher Scientific Inc., Waltham, MA, USA) and Dulbecco's Modified Eagle Medium (DMEM, Gibco) with 10% FBS, respectively. All cells were incubated at 37°C in a humidified incubator with 5% CO_2 incubator. Cells from the third repeated culture were used for experiments. The SRB assay as describe in previous publication [42] was used

to evaluate the antiproliferative activity of all isolated compounds **1–17** against human glioma U87MG and C251 cells. Doxorubicin (DOX) was used as a positive control. Briefly, glioma cells in logarithmic growth (4×10^3 cells/well) were plated in a 96-well plate, treated with different concentrations of each tested compound after 24 h of cells adhesion, and then incubated for 72 h. After that, the treated cells were fixed with 50 µL of 50% cold TCA (trichloroacetic acid) solution at 4 °C for 1 h, washed with distilled water five times, and then dried at 37 °C in a drying oven. The dried cells were stained with 50 µL of 0.4% SRB for 15 min, rinsed with 1% glacial acetic acid solution five times, then dried at 37 °C. Finnally, the dried dye was dissolved in 100 µL of 10 mM Tris buffer and the optical density (OD) value measured at 515 nm on a microplate reader (BioTech, Winooski, VT, USA). The cell viability (%) was calculated from the formula of $T_{OD}/C_{OD} \times 100\%$ (T_{OD}: OD value of tested compound; C_{OD}: OD value of negative control) and IC_{50} value was obtained based on the cell viability (%) by logistic calculation using SPSS software.

4. Conclusions

Chemical investigation of the metabolites produced by the marine-sourced fungus *Penicillium* sp. ZZ1750 cultured in rice medium resulted in the characterization of seven new compounds: peniresorcinosides A–E (**1–5**), penidifarnesylin A (**6**), and penipyridinone A (**7**), which enrich the structural diversity of the metabolites of marine *Penicillium* fungi. Peniresorcinosides A (**1**) and C (**2**) are rare glycosylated alkylresorcinols and had potent antiproliferative activity against both human glioma U87MG and U251 cells and might be the main components responsible for the antiglioma activity of the crude extract prepared the culture of strain ZZ1750 in rice medium.

References

1. Bush, N.A.; Chang, S.M.; Berger, M.S. Current and future strategies for treatment of glioma. *Neurosurg. Rev.* **2017**, *40*, 1–14. [CrossRef] [PubMed]
2. Chamberlain, M.C. Temozolomide: Therapeutic limitations in the treatment of adult high-grade gliomas. *Expert Rev. Neurother.* **2010**, *10*, 1537–1544. [CrossRef] [PubMed]
3. Patil, S.A.; Hosni-Ahmed, A.; Jones, T.S.; Patil, R.; Pfeffer, L.M.; Miller, D.D. Novel approaches to glioma drug design and drug screening. *Expert Opin. Drug Discov.* **2013**, *8*, 1135–1151. [CrossRef]
4. Mooney, J.; Bernstock, J.D.; Ilyas, A.; Ibrahim, A.; Yamashita, D.; Markert, J.M.; Nakano, I. Current approaches and challenges in the molecular therapeutic targeting of glioblastoma. *World Neurosurg.* **2019**, *129*, 90–100. [CrossRef] [PubMed]
5. Rateb, M.E.; Ebel, R. Secondary metabolites of fungi from marine habitats. *Nat. Prod. Rep.* **2011**, *28*, 290–344. [CrossRef]
6. Hasan, S.; Ansari, M.I.; Ahmad, A.; Mishra, M. Major bioactive metabolites from marine fungi: A Review. *Bioinformation* **2015**, *11*, 176–181. [CrossRef]
7. Imhoff, J.F. Natural products from marine fungi—Still an underrepresented resource. *Mar. Drugs* **2016**, *14*, 19. [CrossRef]
8. El-Demerdash, A.; Kumla, D.; Kijjoa, A. Chemical diversity and biological activities of meroterpenoids from marine derived-fungi: A comprehensive update. *Mar. Drugs* **2020**, *18*, 317. [CrossRef]
9. Ma, H.G.; Liu, Q.; Zhu, G.L.; Liu, H.S.; Zhu, W.M. Marine natural products sourced from marine-derived *Penicillium* fungi. *J. Asian Nat. Prod. Res.* **2016**, *18*, 92–115. [CrossRef]
10. Zhang, P.; Wei, Q.; Yuan, X.; Xu, K. Newly reported alkaloids produced by marine-derived *Penicillium* species (covering 2014–2018). *Bioorg. Chem.* **2020**, *99*, 103840. [CrossRef]
11. Yang, X.; Liu, J.; Mei, J.; Jiang, R.; Tu, S.; Deng, H.; Liu, J.; Yang, S.; Li, J. Origins, structures, and bioactivities of secondary metabolites from marine-derived *Penicillium* fungi. *Mini. Rev. Med. Chem.* **2021**, *21*. [CrossRef]
12. Liang, Y.; Xie, X.; Chen, L.; Yan, S.L.; Ye, X.W.; Anjum, K.; Huang, H.C.; Lian, X.Y.; Zhang, Z.Z. Bioactive polycyclic quinones from marine *Streptomyces* sp. 182SMLY. *Mar. Drugs* **2016**, *14*, 10. [CrossRef] [PubMed]
13. Ye, X.W.; Anjum, K.; Song, T.F.; Wang, W.L.; Liang, Y.; Chen, M.X.; Huang, H.C.; Lian, X.Y.; Zhang, Z.Z. Antiproliferative cyclodepsipeptides from the marine actinomycete *Streptomyces* sp. P11-23B downregulating the tumor metabolic enzymes of glycolysis, glutaminolysis, and lipogenesis. *Phytochemistry* **2017**, *135*, 151–159. [CrossRef]
14. Chen, L.; Chai, W.Y.; Wang, W.L.; Song, T.F.; Lian, X.Y.; Zhang, Z.Z. Cytotoxic bagremycins from mangrove-derived *Streptomyces* sp. Q22. *J. Nat. Prod.* **2017**, *80*, 1450–1456. [CrossRef] [PubMed]
15. Song, T.F.; Chen, M.X.; Chai, W.Y.; Zhang, Z.Z.; Lian, X.Y. New bioactive pyrrospirones C-I from a marine-derived fungus *Penicillium* sp. ZZ380. *Tetrahedron* **2018**, *74*, 884–891. [CrossRef]
16. Song, T.F.; Tang, M.M.; Ge, H.J.; Chen, M.X.; Lian, X.Y.; Zhang, Z.Z. Novel bioactive penicipyrroether A and pyrrospirone J from the marine-derived *Penicillium* sp. ZZ380. *Mar. Drugs* **2019**, *17*, 292. [CrossRef]
17. Chen, M.X.; Chai, W.Y.; Song, T.F.; Ma, M.Z.; Lian, X.Y.; Zhang, Z.Z. Anti-glioma natural products downregulating tumor glycolytic enzymes from marine actinomycetes *Streptomyces* sp. ZZ406. *Sci. Rep.* **2018**, *8*, 72. [CrossRef] [PubMed]
18. Zhang, D.; Yi, W.W.; Ge, H.J.; Zhang, Z.Z.; Wu, B. Bioactive streptoglutarimides A–J from the marine-derived *Streptomyces* sp. ZZ741. *J. Nat. Prod.* **2019**, *82*, 2800–2808. [CrossRef]
19. Qin, L.; Yi, W.W.; Lian, X.Y.; Zhang, Z.Z. Bioactive alkaloids from the actinomycete *Actinoalloteichus* sp. ZZ1866. *J. Nat. Prod.* **2020**, *83*, 2686–2695. [CrossRef]
20. Price, N.P.J. Acylic sugar derivatives for GC/MS analysis of ^{13}C-enrichment during carbohydrate metabolism. *Anal. Chem.* **2004**, *76*, 6566–6574. [CrossRef]
21. Kaouadji, M.; Bennini, B.; Chulia, A.J. Two additional 1,9-diarylnonanoid 3-glucosides from *Erica cinerea* among which an unusual α-dione in conformational equilibrium. *Tetrahedron Lett.* **2012**, *53*, 3663–3667. [CrossRef]
22. Lodewyk, M.W.; Siebert, M.R.; Tantillo, D.J. Computational prediction of ^{1}H and ^{13}C chemical shifts: A useful tool for natural product, mechanistic, and synthetic organic chemistry. *Chem. Rev.* **2012**, *112*, 1839–1862. [CrossRef] [PubMed]
23. Grimblat, N.; Zanardi, M.M.; Sarotti, A.M. Beyond DP4: An improved probability for the stereochemical assignment of isomeric compounds using quantum chemical calculations of NMR shifts. *J. Org. Chem.* **2015**, *80*, 12526–12534. [CrossRef] [PubMed]
24. Marwah, R.G.; Fatope, M.O.; Deadman, M.L.; Al-Maqbali, Y.M.; Husband, J. Musanahol: A new aureonitol-related metabolite from a Chaetomium sp. *Tetrahedron* **2007**, *63*, 8174–8180. [CrossRef]
25. Zeng, J.X.; Xu, B.B.; Bi, Y.; Wang, J.; Ren, G.; Wang, H.L.; Zhang, L.; Zuo, H. Chemical constitutes from plantaginis semen (II). *Chin. J. Exp. Trad. Med. Formul.* **2017**, *23*, 81–84.
26. Bordoloi, M.; Saikia, S.; Bordoloi, P.K.; Kolita, B.; Dutta, P.P.; Bhuyan, P.D.; Dutta, S.C.; Rao, P.G. Isolation, characterization and antifungal activity of very long chain alkane derivatives from *Cinnamomum obtusifolium*, *Elaeocarpus lanceifolius* and *Baccaurea sapida*. *J. Mol. Struct.* **2017**, *1142*, 200–210. [CrossRef]
27. Hensens, O.D.; Wichmann, C.F.; Liesch, J.M.; VanMiddlesworth, F.L.; Wilson, K.E.; Schwartz, R.E. Structure elucidation of restricticin, a novel antifungal agent from *Penicillium restrictum*. *Tetrahedron* **1991**, *47*, 3915–3924. [CrossRef]
28. Matsukuma, S.; Ohtsuka, T.; Kotaki, H.; Shirai, H.; Sano, T.; Watanabe, K.; Nakayama, N.; Itezono, Y.; Fujiu, M.; Shimma, N.; et al. A new series of natural antifungals that inhibit P450 lanosterol C-14 demethylase I. Taxonomy, fermentation, isolation and structural elucidation. *J. Antibiot.* **1992**, *45*, 151–159. [CrossRef]

29. Barrett, A.G.M.; Bennett, A.J.; Menzer, S.; Smith, M.L.; White, A.J.P.; Williams, D.J. Applications of crotonyl diisopino campheyl boranes in synthesis: Total synthesis of restrictinol. *J. Org. Chem.* **1999**, *64*, 162–171. [CrossRef]

30. He, W.J.; Zhou, X.J.; Qin, X.C.; Mai, Y.X.; Lin, X.P.; Liao, S.R.; Yang, B.; Zhang, T.Y.; Tu, Z.C.; Wang, J.F.; et al. Quinone/hydroquinone meroterpenoids with antitubercular and cytotoxic activities produced by the sponge-derived fungus *Gliomastix* sp. ZSDS1-F7. *Nat. Prod. Res.* **2017**, *31*, 604–609. [CrossRef]

31. Li, X.J.; Zhang, Q.; Zhang, A.L.; Gao, J.M. Metabolites from *Aspergillus fumigatus*, an endophytic fungus associated with *Melia azedarach*, and their antifungal, antifeedant, and toxic activities. *J. Agric. Food Chem.* **2012**, *60*, 3424–3431. [CrossRef]

32. Zhang, L.M.; Li, Z.L.; Bai, J.; Wu, X.; Wang, Y.; Hua, H.M. Metabolites of *Aspergillus* sp. HT-2. *Chin. Pharm. J.* **2011**, *46*, 1154–1158.

33. Wang, W.L.; Wang, L.P.; Wang, C.; Liu, H.S.; Hao, J.J.; Zhu, W.M. Alkaloids from *Aspergillus* sp. OUCMDZ-3658 associated with soft coral. *Chin. J. Mar. Drugs* **2015**, *34*, 1–11.

34. Afiyatullov, S.S.; Kalinovskii, A.I.; Pivkin, M.V.; Dmitrenok, P.S.; Kuznetsova, T.A. Fumitremorgins from the marine isolate of the fungus *Aspergillus fumigatus*. *Chem. Nat. Comp.* **2004**, *40*, 615–617. [CrossRef]

35. Kaleem, S.; Qi, L.; Yi, W.W.; Lian, X.Y.; Zhang, Z.Z. Bioactive metabolites from the Mariana Trench sediment-derived fungus *Penicillium* sp. SY2107. *Mar. Drugs* **2020**, *18*, 258. [CrossRef]

36. Zhang, M.; Fang, Y.C.; Zhu, T.J.; Zhao, W.Y.; Gu, Q.Q.; Zhu, W.M. Study on indole-quinazolines alkaloids from marine-derived fungus *Aspergillus sydowi* PFW-13 and their antitumor activities. *Chin. Pharm. J.* **2007**, *42*, 1848–1851.

37. Zhang, D.H.; Noviendri, D.; Nursid, M.; Yang, X.D.; Son, B.W. 12,13-Dihydroxyfumitremorgin C, fumitremorgin C, and brevianamide F, antibacterial diketopiperazine alkaloids from the marine-derived fungus *Pseudallescheria* sp. *Nat. Prod. Sci.* **2007**, *13*, 251–254.

38. Campbell, J.; Lin, Q.; Geske, G.D.; Blackwell, H.E. New and unexpected insights into the modulation of LuxR-type quorum sensing by cyclic dipeptides. *ACS Chem. Biol.* **2009**, *4*, 1051–1059. [CrossRef]

39. Thi, Q.V.; Tran, V.H.; Mai, H.D.; Le, C.V.; Hong, M.T.; Murphy, B.T.; Chau, V.M.; Pham, V.C. Secondary metabolites from an actinomycete from Vietnam's East Sea. *Nat. Prod. Commun.* **2016**, *11*, 401–404. [CrossRef]

40. Zhang, H.C.; Liu, R.; Zhou, F.; Wang, R.M.; Liu, X.C.; Zhang, H.T. Antimicrobial metabolites from the endophytic fungus A*spergillus* sp. of *Eucommia ulmoides*. *Chem. Nat. Comp.* **2014**, *50*, 526–528. [CrossRef]

41. Zuo, M.X.; Zhou, Y.L.; Xu, Y.C.; Liu, W.; Zhu, W.M.; Wang, L.P. Secondary metabolites of *Aspergillus fumigatus* GZWMJZ-152 cultivated on *Camellia* seed cake medium. *Mycosystema* **2019**, *38*, 264–271.

42. Xin, W.X.; Ye, X.W.; Yu, S.R.; Lian, X.Y.; Zhang, Z.Z. New capoamycin-type antibiotics and polyene acids from marine *Streptomyces fradiae* PTZ0025. *Mar. Drugs* **2012**, *10*, 2388–2402. [CrossRef]

43. Ross, A.B.; Shepherd, M.J.; Schüpphaus, M.; Sinclair, V.; Alfaro, B.; Kamal-Eldin, A.; Åman, P. Alkylresorcinols in cereals and cereal products. *J. Agric. Food Chem.* **2003**, *51*, 4111–4118. [CrossRef]

44. Kozubek, A.; Tyman, J.H.P. Resorcinolic lipids, the natural non-isoprenoid phenolic amphiphiles and their biological activity. *Chem. Rev.* **1999**, *99*, 1–26. [CrossRef]

45. Choi, B.K.; Phan, T.H.T.; Hwang, S.; Oh, D.C.; Kang, J.S.; Lee, H.S.; Ngo, T.D.N.; Tran, T.T.V.; Shin, H.J. Resorcinosides A and B, glycosylated alkylresorcinols from a marine-derived strain of the fungus *Penicillium janthinellum*. *J. Nat. Prod.* **2019**, *82*, 3186–3190. [CrossRef] [PubMed]

46. Zhang, H.C.; Liu, R.; Yang, J.X.; Li, H.; Zhou, F. Bioactive alkaloids of *Aspergillus fumigatus*, an endophytic fungus from *Astragalus membranaceus*. *Chem. Nat. Comp.* **2017**, *53*, 802–805. [CrossRef]

47. Takahashi, C.; Matsushita, T.; Doi, M.; Minoura, K.; Shingu, T.; Kumeda, Y.; Numata, A. Fumiquinazolines A-G, novel metabolites of a fungus separated from a *Pseudolabrus* marine fish. *J. Chem. Soc. Perk. Trans. 1* **1995**, *18*, 2345–2353. [CrossRef]

48. Resende, D.I.S.P.; Boonpothong, P.; Sousa, E.; Kijjoa, A.; Pinto, M.M.M. Chemistry of the fumiquinazolines and structurally related alkaloids. *Nat. Prod. Rep.* **2019**, *36*, 7–34. [CrossRef]

49. Li, C.J.; Chen, P.N.; Li, H.J.; Mahmud, T.; Wu, D.L.; Xu, J.; Lan, W.J. Potential antidiabetic fumiquinazoline alkaloids from the marine-derived fungus *Scedosporium apiospermum* F41-1. *J. Nat. Prod.* **2020**, *83*, 1082–1091. [CrossRef] [PubMed]